Skip to main content
Shanghai Aladdin Biochemical Technology Co., Ltd. logo

Shanghai Aladdin Biochemical Technology Co., Ltd. — Investor Relations & Filings

Ticker · 688179 ISIN · CNE100005XD0 LEI · 300300VW4LSHJ5HTMH32 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 845 across all filing types
Latest filing 2026-05-20 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688179

About Shanghai Aladdin Biochemical Technology Co., Ltd.

https://www.aladdin-e.com/

Shanghai Aladdin Biochemical Technology Co., Ltd. is a specialized developer and manufacturer of high-quality chemical reagents, laboratory consumables, and life science products. The company offers an extensive portfolio that includes analytical reagents, organic and inorganic chemicals, biochemical reagents, and materials science reagents. Its products are designed to meet the rigorous standards of research institutions, pharmaceutical companies, and industrial laboratories. Aladdin focuses on providing high-purity substances and innovative solutions to support a wide range of applications in scientific research, environmental monitoring, and diagnostic testing. By maintaining a strong emphasis on research and development and quality assurance, the company serves as a critical supplier for the global scientific community, facilitating advancements in biotechnology and chemical synthesis.

Recent filings

Filing Released Lang Actions
阿拉丁关于调整2025年度利润分配现金分红总额的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal board announcement by Shanghai Aladdin Biochemical Technology Co., Ltd. concerning the adjustment of the total cash dividend amount for the 2025 annual profit distribution. It specifies the per-share dividend, total dividend amount before and after share count changes due to convertible bond conversions and incentive plan share issuances, and details of the revised distribution plan. This is a dividend distribution notice, matching the “Notice of Dividend Amount” category.
2026-05-20 Chinese
阿拉丁2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an official announcement of the resolutions passed at the 2025 Annual General Meeting of Shanghai Aladdin Biotech Technology Co., Ltd. It details attendance, agenda items, vote counts and percentages, and legally required confirmations. This aligns precisely with the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-19 Chinese
上海市锦天城律师事务所关于上海阿拉丁生化科技股份有限公司2025年年度股东会的法律意见书
Legal Proceedings Report Classification · 62% confidence The document is a legal opinion letter (“法律意见书”) prepared by a law firm regarding the legality of the company’s 2025 annual shareholders’ meeting procedures, attendance, and resolutions. It is not an AGM presentation, voting result announcement, or financial report; rather, it addresses legal compliance and due process. The closest category for such legal advice on company governance matters is a legal proceedings report.
2026-05-19 Chinese
阿拉丁关于更换持续督导保荐代表人的公告
Regulatory Filings Classification · 85% confidence The document is an official exchange filing announcing a change in the company’s continuous sponsorship representatives (保荐代表人) by its sponsoring broker. This is not a full financial report, earnings release, share issue, director trade, or management/board directorship change. It is a regulatory announcement that does not neatly fit another category, so it falls under the general Regulatory Filings (RNS) category.
2026-05-14 Chinese
阿拉丁关于“阿拉转债”赎回结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the redemption results of a convertible bond ("阿拉转债") and the related changes in share capital. It details the redemption quantity, payment date, bond delisting date, and the impact on the company's share capital structure. The document is relatively short (2400 characters) and focuses on the redemption event and shareholding changes rather than providing comprehensive financial statements or detailed financial analysis. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a management discussion or earnings release. The content fits best with a Capital/Financing Update (CAP) as it relates to financing activities, specifically the redemption of convertible bonds and the resulting capital structure changes.
2026-05-06 Chinese
阿拉丁2025年度独立董事述职报告（马如适）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, participation in board meetings, committee involvement, communication with auditors, and other governance-related activities during the fiscal year 2025. The content focuses on the independent director's responsibilities, evaluations, and opinions on company governance, internal controls, and related matters. It does not contain financial statements or quarterly results, nor is it an announcement or proxy solicitation. It is a management/governance-related report by a board member about their role and activities. This fits best under Board/Management Information (MANG) as it relates to board member duties and governance reporting rather than a full annual report or audit report. The document length (4534 characters) and detailed content support this classification with high confidence.
2026-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.